Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 26 January 2009, doi:10.1136/bmj.b181
Cite this as: BMJ 2009;338:b181
Adrian Towse, director
1 Office of Health Economics, London SW1A 2DY
atowse@ohe.org
NICE has recently raised the threshold for end of life drugs. Adrian Towse argues it should consider doing the same for other treatments, but James Raftery (doi:10.1136/bmj.b185) believes that the threshold is already too high
| The first 150 words of the full text of this article appear below. |
Decisions made by the National Institute for Health and Clinical Excellence (NICE) about whether the NHS should fund treatments are based on cost effectiveness. NICE methods guides refer to a threshold of £20 000-£30 000 (
22 000-
34 000; $30 000-$45 000) per quality adjusted life year (QALY).1 However, this is an arbitrary figure. Evidence on the publics willingness to pay suggests that it should be higher. There is a lack of evidence on opportunity costs.
The Department of Health has commissioned research to help it understand what the public wants the NHS to pay for health gain in the knowledge that it has limited resources and pays for care from taxes. This estimates willingness to pay at £30 000 to £70 000 per QALY.2 On this basis NICEs threshold range should double.
The willingness to pay approach is usually challenged on two grounds. Firstly, it is argued that
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses